Navigation Links
Wayne State-licensed technology receives grant from the Foundation Fighting Blindness
Date:2/15/2012

DETROIT Technology to restore vision through the use of a component of green algae developed by a Wayne State University professor and scientific director of the Ligon Research Center of Vision at the Kresge Eye Institute has attracted additional funding for therapy development.

The Foundation Fighting Blindness announced a $250,000 grant from their affiliate, National Neurovision Research Institute, to RetroSense Therapeutics, LLC, a Michigan-based company. RetroSense signed a license agreement in 2011 for the novel gene-therapy approaches developed at Wayne State University by Zhuo-Hua Pan, Ph.D., professor of ophthalmology and anatomy & cell biology in the School of Medicine.

Pan's novel strategy focused on genetically converting light-insensitive inner retinal neurons into photosensitive cells, thus restoring light sensitivity to retinas that lack photoreceptors. Using a virus that delivers a photoreceptor gene from green algae called channelrhodopsin-2 (ChR2), he found that ChR2 made the inner retinal neurons light sensitive, and that this persisted for long periods in the neurons, ultimately leading to restored responses to light in the brain's visual cortex.

Pan, along with colleagues at Salus University in Pennsylvania, developed the breakthrough therapy and follow-on approaches that offer promise to people suffering with blindness caused by age-related macular degeneration (AMD) and retinitis pigmentosa (RP) retinal degenerative disorders that are currently incurable.

AMD is the leading cause of blindness in people older than 60, affecting more than 8 million in the United States. Worldwide, 500,000 individuals lose their eyesight annually to AMD, which is the result of progressive deterioration of photoreceptor cells in the macula, near the center of the retina.

RP is a genetically-determined eye disease caused by mutations in more than 100 different genes. An estimated 100,000 Americans have RP, which typically manifests as night blindness and progresses to tunnel vision and sometimes complete blindness.

"This field of research, known as optogenetics, is a very promising and creative approach to restoring vision in people with severe vision loss or complete blindness," said Stephen Rose, M.D., the foundation's chief research officer, in a news release. "RetroSense has outstanding technology, and it has achieved impressive results in lab studies. We are pleased to support the company in its effort to move the treatment into a clinical trial."

Rose said an advantage of optogenetic treatments is that because they work independently of genetic defects causing disease, they may work for a variety of retinal degenerations.

The foundation said the therapy developed by Pan has demonstrated restored vision in animal models with highly degenerated retinas. RetroSense Therapeutics is seeking U.S. Food and Drug Administration approval for a Phase I clinical trial.

Sean Ainsworth, founder and chief executive officer of RetroSense, licensed the technology from Wayne State University. He has said that Phase I clinical trials could begin in early 2013.


'/>"/>
Contact: Julie O'Connor
julie.oconnor@wayne.edu
313-577-8845
Wayne State University - Office of the Vice President for Research
Source:Eurekalert

Related biology news :

1. Wayne State University researchers model will target causes of everyday MS symptoms
2. Wayne State study finds soybean compounds enhances effects of cancer radiotherapy
3. Better CMT outcome measurement is Wayne State University physicians goal
4. Wayne State announces license agreement for breakthrough approaches to vision restoration
5. EPA grants help Wayne State researchers stave off Great Lakes environmental invaders
6. Wayne State start-up company NextCAT awarded nearly $500,000 from NSF for Phase II SBIR
7. Wayne State researcher discovers antibiotic useful for localized treatment of bone wear
8. Wayne State to study the role of vitamin D in African-Americans with high blood pressure
9. Wayne State University chosen as Michigans sole participant in EcoCAR 2
10. Soy increases effectiveness of radiation at killing lung cancer, Wayne State study shows
11. NextCAT secures license agreement for advanced biofuel technology from Wayne State
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, ... faculty of the University of North Carolina Kenan-Flagler Business School effective ... at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading classes ...
(Date:6/27/2016)...   Ginkgo Bioworks , a leading organism ... today awarded as one of the World Economic ... most innovative companies. Ginkgo Bioworks is engineering biology ... world in the nutrition, health and consumer goods ... customers including Fortune 500 companies to design microbes ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
Breaking Biology Technology: